Automating Rheumatology CGM Prior Auth

For rheumatology practices, managing the complex landscape of prior authorizations extends to essential supportive care like continuous glucose monitors. Klivira streamlines **rheumatology CGM prior auth** for patients with co-occurring diabetes.

Patients with chronic rheumatic conditions often have comorbidities, including diabetes, requiring precise glucose management. Navigating prior authorizations for continuous glucose monitors (CGMs) adds administrative burden to an already complex PA workflow dominated by high-cost biologics. Klivira provides a unified solution to manage these diverse PA requirements efficiently.

The Dual Challenge: Rheumatology Biologics and CGM Prior Auth

Rheumatology practices face a significant prior authorization burden primarily driven by advanced therapies such as biologics and JAK inhibitors, critical for managing conditions like RA, PsA, and AS. Simultaneously, a subset of these patients requires continuous glucose monitoring (CGM) for diabetes management, introducing a distinct set of authorization requirements that must be handled alongside their primary rheumatology treatments.

Understanding CGM Prior Authorization in a Rheumatology Context

While the core of rheumatology PA focuses on disease-modifying agents, the need for CGM prior auth arises when patients with autoimmune conditions also have diabetes. This requires documentation specific to diabetes type and insulin dependence, alongside the ongoing management of their rheumatic disease. Klivira integrates these distinct workflows, ensuring all necessary documentation is captured for both initial CGM authorization and subsequent supply re-authorization.

Key Documentation for Continuous Glucose Monitors

Diagnosis of Type 1 or Type 2 Diabetes (ICD-10)
Documentation of insulin dependence or intensive insulin regimen
History of hypoglycemia or hyperglycemia requiring monitoring
Physician's order for a continuous glucose monitoring device (e.g., Dexcom, Libre)
Anticipated duration of CGM use and supply re-authorization frequency

Integrating CGM Workflows with Rheumatology PA Management

Klivira's platform connects directly with EMR systems, pulling relevant patient data for both rheumatology-specific PAs (like those for biologics such as Humira or Enbrel) and CGM authorizations. This integration ensures that clinical templates for diabetes management, alongside those for autoimmune disease activity (e.g., DAS28, PASI), contribute to a comprehensive PA submission. The system routes requests through appropriate payer channels, including X12 278 transactions or payer portals.

Streamlining Re-authorization for Chronic Conditions

Both chronic rheumatic conditions and diabetes requiring CGM involve ongoing management and periodic re-authorization. Klivira automates the re-authorization workflow for biologics, which typically require continuous documentation of disease response, and extends this capability to CGM supply re-authorization, ensuring uninterrupted access to critical devices for patients.

Klivira's Comprehensive Approach to Diverse PA Needs

Klivira provides a robust solution for the varied prior authorization demands within rheumatology. This includes managing the complexities of biologic step therapy, biosimilar substitution, and medical-vs-pharmacy benefit splits, while also efficiently handling ancillary but critical authorizations like those for continuous glucose monitors. Our platform helps practices maintain compliance with payer-specific policies and clinical guidelines, such as those from the ACR.

Frequently asked questions

How does Klivira handle both biologic and CGM prior authorizations simultaneously?

Klivira's platform is designed to manage diverse prior authorization workflows concurrently. It integrates EMR data for both rheumatology-specific treatments and CGM requirements, allowing for comprehensive documentation capture and submission through the appropriate payer channels, whether via X12 278 or specific payer portals.

What documentation is typically required for CGM prior auth in rheumatology patients?

For continuous glucose monitor prior authorizations, payers typically require documentation of diabetes type (Type 1 or Type 2), evidence of insulin dependence or an intensive insulin regimen, and a physician's order for the device. Klivira helps aggregate this necessary clinical information from your EMR.

Can Klivira manage re-authorizations for continuous glucose monitors?

Yes, Klivira automates the re-authorization process for both chronic rheumatology treatments and continuous glucose monitors. Our system tracks re-authorization cadences and prompts for necessary updated documentation, ensuring patients maintain access to their devices without administrative delays.

Does Klivira integrate with our EMR to pull CGM-specific patient data?

Klivira offers robust EMR integration capabilities, including SMART on FHIR, to securely extract relevant patient data. This includes clinical notes, lab results, and medication lists pertinent to both rheumatology conditions and diabetes management, streamlining the documentation process for CGM prior authorizations.

How does Klivira address payer policy variations for CGM approvals?

Klivira maintains an extensive, dynamically updated library of payer policies. For CGM authorizations, this means our system can identify and apply specific criteria related to diabetes type, insulin use, and device models, helping ensure submissions align with individual payer requirements and reduce denials.